Our Team

Dr Mian Bi is the Medical Director of Geneve Health, providing clinical leadership and oversight across patient experience, medical governance, and the translation of genetics into genomic-led care pathways. He is a practising emergency clinician and neuroscientist with deep experience across clinical practice, research, and healthcare innovation.

Dr Bi has worked closely with Kate Freeman to leverage the infrastructure and capabilities of 23Strands to design and implement an integrated genetics-to-genomics pathway, ensuring Geneve Health’s model is clinically rigorous, scalable, and fit for mainstream medicine.

He is the founder of the Investing for Doctors community, an education-led platform supporting more than 29,000 verified medical and dental practitioners across Australia. Through this work, he has developed a strong understanding of clinician engagement, education, and system-level change. He also operates a regional multispecialty clinic, giving him practical insight into the needs of patients and clinicians across metropolitan, rural, and regional settings.

Dr Bi is co-GP of Med Angels, Australia’s leading healthcare investment syndicate, and acts as an investor and advisor to healthcare start-ups. A published neuroscientist with more than 3,500 citations, he is a Visiting Research Fellow at Macquarie University and a Chief Investigator on NHMRC and MRFF grants. At Geneve Health, he ensures clinical excellence, patient safety, and evidence-based innovation remain central to the company’s mission.

Dr Hua Lin is the Chief Data Officer of Geneve Health, responsible for the company’s data, artificial intelligence, and advanced analytics strategy underpinning genomic interpretation and clinical decision support. She is a recognised leader in data science and AI, with more than 20 years of experience translating complex data into real-world impact across science, healthcare, and industry.

Hua combines deep technical expertise in big data, machine learning, and AI system design with strong strategic leadership. She has led the development of AI platforms that deliver measurable commercial and scientific outcomes, with a particular focus on translational research — converting discovery-level insights into scalable, applied solutions.

She has collaborated with the Australian Artificial Intelligence Institute at the University of Technology Sydney for more than a decade, leading multiple industry-research partnerships. Her work includes the development of AI-driven bibliometric and gene-disease intelligence systems now embedded within 23Strands and Geneve Health to support genomic research, clinical interpretation, and competitive intelligence.

Hua has secured major competitive research funding, including ARC Linkage, MRFF, and ARC Industry Laureate grants, and has authored 28 peer-reviewed publications. At Geneve Health, she ensures the responsible, robust, and clinically meaningful use of AI to accelerate genomic insight while maintaining the highest standards of scientific integrity.

Lisa Andrews is an Executive Director of 23 Strands Pty Ltd, of which Geneve Health is a wholly owned subsidiary. She brings deep experience in executive leadership, innovation, and strategic governance, with a career focused on scaling technology-led organisations with global ambition.

Lisa previously served as Co-CEO of Singularity University Australia, where she led initiatives supporting high-impact ventures and emerging technologies aimed at solving complex global challenges. Her leadership is grounded in purpose-driven strategy, with a strong focus on aligning innovation, commercial outcomes, and long-term societal impact.

Motivated by personal health experiences, Lisa has a strong commitment to advancing women’s health and improving health equity through technology and innovation. Her role with Geneve Health is focused on stewardship, strategic direction, and ensuring the organisation is positioned for sustainable, values-led growth.

Mark Grosser is an Executive Director of Geneve Health and a co-founder and Executive Director of 23 Strands Pty Ltd, of which Geneve Health is a wholly owned subsidiary. He brings more than 30 years’ experience in health technology across engineering, research and development, and executive leadership, with senior roles at Cochlear, Micromedical, and the Henry Schein Group.

With a background in high-technology engineering, healthcare data analysis, and medical devices, Mark has played a key role in setting the strategic direction for 23Strands’ genomic capabilities and the governance frameworks that support them. His experience has been instrumental in establishing robust, clinically credible platforms and organisational structures.

Under his leadership, 23Strands grew through the pandemic and became a recognised leader in genomic solutions supporting reproductive and women’s health in Australia. At Geneve Health provides strategic input and oversight and continues to support the business through the 23Strands board, to which Geneve Health ultimately reports.